II

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

Retrieved on: 
星期三, 四月 24, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Information, Acalabrutinib, Colorectal cancer, BCL2, Follicular lymphoma, Patient, Comparison, TIS, HPK1, Tislelizumab, Lymphoid leukemia, Pharmaceutical industry

Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis

Key Points: 
  • Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis
    Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL)
    BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
    Session Type and Title: Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
    Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: an open-label, single-arm, multicenter phase II study
    Tislelizumab First-Line (1L) Gastric/Gastroesophageal Junction Cancer (G/GEJ) Treatment Efficacy on PRO-Based Symptom Endpoints Adjusting for Informative Missing Data Bias: Results from RATIONALE 305
    A first‑in‑human phase 1a dose‑escalation study of BGB‑15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti‑PD‑1 antibody) in patients (pts) with advanced solid tumors
    Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements

Retrieved on: 
星期二, 四月 23, 2024
Technology, Finance, Apps, Applications, Consulting, Professional Services, Artificial Intelligence, IOT (Internet of Things), Networks, Data Analytics, Internet, Fintech, Data Management, Security, Consumer Electronics, COVID, Federico, STAR, MTA, Financial statement, Documentation, Shareholder, Record, Paragraph, Acquisition, Remuneration, EXM, Alternative, Share repurchase, Legislature, TUF

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share.

Key Points: 
  • The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share.
  • The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022.
  • (owner of a 39.754% shareholding in Reply S.p.A.), which obtained the highest number of votes (63.821% of votes obtained).
  • The Shareholders' Meeting also approved Sections I and II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.

Halliburton Announces First Quarter 2024 Results

Retrieved on: 
星期二, 四月 23, 2024
Other Energy, Mining, Minerals, Oil, Gas, Energy, Natural Resources, Nuclear, Net income, International, HAL, Completion, S4, Elasticity, Carbon, Gulf of Mexico, CCUS, Porosity, Pressure, CO2, Evaluation, Partner, Video game

Halliburton's total revenue for the first quarter of 2024 was $5.8 billion, a 2% increase when compared to the first quarter of 2023.

Key Points: 
  • Halliburton's total revenue for the first quarter of 2024 was $5.8 billion, a 2% increase when compared to the first quarter of 2023.
  • Operating income was $987 million in the first quarter of 2024, flat when compared to the first quarter of 2023.
  • "Halliburton delivered solid first quarter results that again demonstrated the power of our strategy and the strength of our execution.
  • North America revenue in the first quarter of 2024 was $2.5 billion, an 8% decrease when compared to the first quarter of 2023.

ERI Receives Highest Customer Rating Score in Compliance Standards’ 2024 ITAD Vendor Reputation Survey

Retrieved on: 
星期二, 四月 16, 2024
Sustainability, Environment, Hardware, Environmental, Social and Governance (ESG), Recycling, Professional Services, Technology, Security, Electronics, Organization, Carbon, Electronic waste, Privacy, SOC, ESG, ERI

Combining the attributes above, ERI was one of only two pure-play ITAD service providers who received the overall 4.5 star customer rating, exhibiting a significant level of loyalty among its clients.

Key Points: 
  • Combining the attributes above, ERI was one of only two pure-play ITAD service providers who received the overall 4.5 star customer rating, exhibiting a significant level of loyalty among its clients.
  • “ERI has been consistently producing some of the best metrics in the ITAD industry,” said David Daoud, Principal Analyst at Compliance Standards LLC.
  • ERI is also one of the most active advocates of ITAD practices in the enterprise, with some of the strongest and most proactive marketing campaigns in favor of good ITAD practices.”
    “Having the highest customer rating score in the ITAD industry as determined by our own clients is a tremendous honor and something we are incredibly proud of,” said ERI Chairman/CEO John Shegerian.
  • “We also thank Compliance Standards for conducting such a thorough and critically important study of customer and employee attitudes in the ITAD space.

Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study

Retrieved on: 
星期一, 四月 15, 2024
Technology, Medical Devices, Neurology, Science, Consumer, Clinical Trials, FDA, Biotechnology, Health, Other Science, Research, Software, Hardware, Radiology, Pharmaceutical, Data Management, Seniors, American Academy, ARIA, Disease, OLE, Patient, Cognito, RCT, Therapy, Frontiers

OVERTURE II enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.

Key Points: 
  • OVERTURE II enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.
  • There was no observed convergence of ADCS-ADL scores between early and delayed start groups in OVERTURE II.
  • No cases of ARIA or serious treatment-related adverse events were reported over 12 months in the 44-patient OVERTURE II study.
  • High device adherence (80%) was reported in OVERTURE II, which was comparable to that observed in OVERTURE I.

VTEX Announces Products to Elevate Commerce Experiences

Retrieved on: 
星期四, 四月 11, 2024
Technology, Marketing, Advertising, Communications, Artificial Intelligence, Metaverse, Retail, Influencer, Social Media, Electronic Commerce, Professional Services, Security, Apps, Applications, Digital Marketing, Data Analytics, Other Technology, Supply Chain Management, Software, Online Retail, Networks, Internet, Payments, Other Communications, Other Retail, CMS, ROI, Ecosystem, UI, Element, AI, Shopper, Commerce, GMV, Sis, B2C, Meta, Headless, Environment, B2B, WhatsApp, API, Algorithm, Marketplace, Online shopping

VTEX (NYSE: VTEX), the composable and complete commerce platform for premier B2C and B2B brands, is set to unveil its latest suite of products poised to shape the future of commerce at VTEX DAY.

Key Points: 
  • VTEX (NYSE: VTEX), the composable and complete commerce platform for premier B2C and B2B brands, is set to unveil its latest suite of products poised to shape the future of commerce at VTEX DAY.
  • Renowned for its commitment to elevating customer experiences, developer workflows, and conversion rates, VTEX will showcase strategies for B2B and B2C enterprises to optimize their commerce platforms and amplify their ROI.
  • VTEX Ad Network: leveraging VTEX vast brand and supplier network to connect customers with perfect advertising partners.
  • VTEX is transforming the commerce landscape with groundbreaking products tailored for enterprise customers, their IT teams, and business teams.

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting

Retrieved on: 
星期三, 四月 24, 2024
Neoplasm, Cancer, Part, Lung cancer, Safety, NDA, Abstract, Doctor of Philosophy, ASCO, Patient, Society, EMA, Annual general meeting, EGFR, NSCLC, Plasma, Platinum, Pharmaceutical industry

SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.

Key Points: 
  • In a featured oral presentation, Dizal will highlight topline results from its WU-KONG1 Part B study.
  • "We are very pleased that the inaugural global pivotal study of sunvozertinib is selected for oral presentation at the 2024 ASCO Annual Meeting again" said Xiaolin Zhang, PhD, CEO of Dizal.
  • It was subsequently approved in China, making sunvozertinib the world first and only oral drug for the treatment of lung cancer patients with EGFR exon20ins mutations.
  • This poster will focus on plasma ctDNA biomarker analysis in patients with EGFR exon20ins NSCLC who have undergone treatment with sunvozertinib.

River Global Selects Bloomberg to Support Streamlined Front-to-Back Workflow

Retrieved on: 
星期二, 四月 23, 2024
MAS, ETF, Automation, EMIR, Operations director, Saracen, Research, Workflow, P&L, SFTR, ESG, Acquisition, ASIC, Bloomberg, Portfolio, FX

River Global offers a focused range of investment options, investing in UK, European, regional and global equity markets.

Key Points: 
  • River Global offers a focused range of investment options, investing in UK, European, regional and global equity markets.
  • "By adopting Bloomberg's integrated offerings, we now have seamless connectivity in our workflow, ensuring efficiency and accuracy across our front, middle and back-office operations," said Phil Jones, Product and Operations Director, River Global.
  • The River Global team is utilizing the full power of Bloomberg AIM, a leading order and investment management technology solution.
  • "Bloomberg is committed to working with clients like River Global who have the need for a comprehensive solutions suite that can align with their current and future workflows," said Raquel Alves, Global Head of Buy-Side OMS, Bloomberg.

GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

Retrieved on: 
星期五, 四月 19, 2024
FDA, Total, Colorectal cancer, Mutation, Immunology, Lung cancer, Priority review, NMPA, National Medical Products Administration, Cetuximab, Progression-free survival, New Drug Application, Irinotecan, Oxaliplatin, Recurrence, RAS, CRC, ESMO, Medicine, ASCO, Canadian International Council, Disease, Incidence, Patient, Liver, Peritoneum, Food and Drug Administration, BTD, Lung, Death, Biology, Clinical trial, EGFR, Therapy, Cancer, NSCLC, Breakthrough therapy, Prevalence, Pharmaceutical industry

"We appreciate the FDA's recognition of GFH925' efficacy and safety profile, as this is our first global phase III monotherapy study in treating advanced stage CRC.

Key Points: 
  • "We appreciate the FDA's recognition of GFH925' efficacy and safety profile, as this is our first global phase III monotherapy study in treating advanced stage CRC.
  • We believe the approval of our proposed trial design highlights the potential of GFH925 monotherapy in this indication, thus bringing more therapeutic options and clinical benefits to the patients.
  • Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver, International Journal of Molecular Science, Mar.
  • Disease Burden of Total and Early-Onset Colorectal Cancer in China from 1990 to 2019 and Predictions of Cancer Incidence and Mortality, Clinical Epidemiology, Feb. 2023
    4.

VSaaS Market worth $10.7 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
星期四, 四月 18, 2024
Cloud, Smoke, VMS, Wet, Investment, Professional, Wildfire, Urbanization, Intelligence, Motorola Solutions, Photoelectric effect, Access control, Monitor, Cloud computing, Video content analysis, Securitas AB, Securitas, IP, DAC, ADT, Hosting, Algorithm, Safety, Thermography, RMON, Transport, Row, RBAC, Organization, Government, Internet, Commercial, Heat detector, Region, Facial recognition, Anomaly, Economic development, Flame detector, Growth, Storage device, Deep learning, Video game

The VSaaS market for hybrid services is experiencing notable growth due to its ability to offer a flexible and customizable approach to video surveillance.

Key Points: 
  • The VSaaS market for hybrid services is experiencing notable growth due to its ability to offer a flexible and customizable approach to video surveillance.
  • VSaaS market for AI-enabled VSaaS to hold the highest CAGR during the forecast period.
  • The VSaaS market for AI-enabled VSaaS is experiencing rapid growth due to the transformative impact of artificial intelligence on video surveillance capabilities.
  • These players have a strong market presence for VSaaS across various North America, Europe, Asia Pacific, and RoW countries.